Patents by Inventor Wolfgang KOTHNY

Wolfgang KOTHNY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY
    Publication number: 20220184006
    Abstract: The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 26, 2021
    Publication date: June 16, 2022
    Inventors: Päivi M. PALDÁNIUS, Wolfgang KOTHNY, James E. FOLEY, David R. MATTHEWS, Michael STUMVOLL, Stefano DEL PRATO
  • Combination therapy
    Patent number: 11103469
    Abstract: The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 31, 2021
    Assignee: Novartis AG
    Inventors: Päivi M. Paldánius, Wolfgang Kothny, James E. Foley, David R. Matthews, Michael Stumvoll, Stefano Del Prato
  • COMBINATION THERAPY
    Publication number: 20210077430
    Abstract: The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Paivi M. PALDANIUS, Wolfgang KOTHNY, James E. FOLEY, David R. MATTHEWS, Michael STUMVOLL, Stefano DEL PRATO